The Roles of CD4+ T-Cells in Tumor Immunity

Tavakolpour, Soheil; Darvishi, Mohammad

doi:10.1007/978-3-030-30845-2_5

Cited by 3 publications

(3 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of CD4+ T cells in cancer is complex and context‐dependent, as they can exert both tumour‐suppressing and tumour‐promoting effects. 29 These correlations underscore the intricate relationship between tumour biology and the immune microenvironment in NSCLC. They also highlight the potential of immune cell profiles as biomarkers for prognosis and as therapeutic targets.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, the increase in activated CD4+ memory T cells in high‐risk samples could reflect a compensatory immune response to tumour progression, or alternatively, these cells might be indicative of a tumour‐promoting inflammatory environment. The role of CD4+ T cells in cancer is complex and context‐dependent, as they can exert both tumour‐suppressing and tumour‐promoting effects 29 . These correlations underscore the intricate relationship between tumour biology and the immune microenvironment in NSCLC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Deciphering the role of cuproptosis‐related lncRNAs in shaping the lung cancer immune microenvironment: A comprehensive prognostic model

Huang,

Chen,

Zhang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Cuproptosis plays an important role in cancer, but its role in lung cancer remains unknown. Transcriptional profiles, clinical details and mutation data were acquired from the Cancer Genome Atlas database through a variety of methods. The analysis of this publicly available data was comprehensively performed using R software along with its relevant packages, ensuring a thorough examination of the information. In this study, we conducted a detailed analysis of cuproptosis‐related genes and lncRNA co‐expression, identifying 129 relevant lncRNAs and establishing a prognostic model with four key lncRNAs (LINC00996, RPARP‐AS1, SND1‐IT1, TMPO‐AS1). Utilizing data from TCGA and GEO databases, the model effectively categorized patients into high‐ and low‐risk groups, showing significant survival differences. Correlation analysis highlighted specific relationships between individual lncRNAs and cuproptosis genes. Our survival analysis indicated a higher survival rate in the low‐risk group across various cohorts. Additionally, the model's predictive accuracy was confirmed through independent prognostic analysis and ROC curve evaluations. Functional enrichment analysis revealed distinct biological pathways and immune functions between risk groups. Tumour mutation load analysis differentiated high‐ and low‐risk groups by their mutation profiles. Drug sensitivity analysis and immune infiltration studies using the CIBERSORT algorithm further elucidated the potential treatment responses in different risk groups. This comprehensive evaluation underscores the significance of lncRNAs in cuproptosis and their potential as biomarkers for lung cancer prognosis and immune microenvironment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Deciphering the role of cuproptosis‐related lncRNAs in shaping the lung cancer immune microenvironment: A comprehensive prognostic model

Huang,

Chen,

Zhang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…KLH is a highly immunogenic protein enriched with T helper (Th) epitopes and has been successfully used as immunostimulants in various human clinical research settings, including studies on infectious, immunotoxicological and autoimmune diseases [ 18 , 19 ]. The importance of Th cells in stimulating antitumor immunity via enhancing and priming effector T-cells, particularly CTL, is well documented [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

HER2/neu-Based Peptide Vaccination-Pulsed with B-Cell Epitope Induced Efficient Prophylactic and Therapeutic Antitumor Activities in TUBO Breast Cancer Mice Model

Nordin

Norpi

et al. 2021

Cancers

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer diagnosed among women. A cancer vaccine has been recognized as a form of immunotherapy with a prominent position in the prevention and treatment of breast cancer. The majority of current breast cancer vaccination strategies aim to stimulate antitumor T-cell responses of the HER2/neu oncogene, which is abnormally expressed in breast cancer cells. However, the role of the B-cell humoral response is often underappreciated in the cancer vaccine design. We have advanced this idea by elucidating the role of B-cells in cancer vaccination by designing a chimeric antigenic peptide possessing both cytotoxic T lymphocytes (GP2) and B-cell (P4) peptide epitopes derived from HER2/neu. The chimeric peptide (GP2–P4) was further conjugated to a carrier protein (KLH), forming a KLH–GP2–P4 conjugate. The immunogenicity of KLH–GP2–P4 was compared with KLH–GP2 (lacking the B-cell epitope) in BALB/c mice. Mice immunized with KLH–GP2–P4 elicited more potent antigen-specific neutralizing antibodies against syngeneic TUBO cells (cancer cell line overexpressing HER2/neu) that was governed by a balanced Th1/Th2 polarization in comparison to KLH–GP2. Subsequently, these immune responses led to greater inhibition of tumor growth and longer survival in TUBO tumor-bearing mice in both prophylactic and therapeutic challenge experiments. Overall, our data demonstrated that the B-cell epitope has a profound effect in orchestrating an efficacious antitumor immunity. Thus, a multi-epitope peptide vaccine encompassing cytotoxic T-lymphocytes, T-helper and B-cell epitopes represents a promising strategy in developing cancer vaccines with a preventive and therapeutic modality for the effective management of breast cancer.

show abstract